1Wilcox Mark H,Corey G Ralph,Talbot George H,Thye Dirk,Friedland David,Baculik Tanya.CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. The Journal of antimicrobial chemotherapy . 2010
2File Thomas M,Wilcox Mark H,Stein Gary E.Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America . 2012
3Citron D M,Tyrrell K L,Merriam C V,Goldstein E J C.In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrobial Agents and Chemotherapy . 2010
4Jacqueline Cédric,Caillon Jocelyne,Le Mabecque Virginie,Miègeville Anne-Fran?oise,Hamel Antoine,Bugnon Denis,Ge James Yigong,Potel Gilles.In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrobial Agents and Chemotherapy . 2007
5Rodrigo E. Mendes,Athanassios Tsakris,Helio S. Sader.Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. Journal of Antimicrobial Chemotherapy . 2012
6Andes D,Craig W A.Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrobial Agents and Chemotherapy . 2006
7Tomoyasu Ishikawa,Nobuyuki Matsunaga,Hiroyuki Tawada,Noritaka Kuroda,Yutaka Nakayama,Yukio Ishibashi,Mitsumi Tomimoto,Yukihiro Ikeda,Yoshihiko Tagawa,Yuji Iizawa,Kenji Okonogi,Shohei Hashiguchi,Akio Miyake.??TAK-599, a novel N -Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties(J)Bioorganic & Medicinal Chemistry . 2003 (11)
